(Z)-4-oxo-4-(quinolin-8-ylamino)but-2-enoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (Z)-4-oxo-4-(quinolin-8-ylamino)but-2-enoic acid
• 化学式: C₁₃H₁₀N₂O₃
• 分子量: 242.23
• InChiKey: VAEDJJPDTRPPQL-SREVYHEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] PHTHALANILATE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PHTALANILATE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV NOTRE DAME DU LAC

  公开号：WO2011026107A1

  公开（公告）日：2011-03-03

  The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo.

  本发明提供了抗微生物化合物和组合物，以及使用它们的方法。这些化合物和组合物包括，例如，I-X公式中的任何一种化合物。本发明进一步提供了制备这些化合物的方法，并提供了有用的中间体。这些化合物可以具有高度特异性和选择性活性，例如抗菌活性和/或酶抑制活性。因此，这些化合物和组合物可以用于治疗细菌感染，或者在体外或体内抑制或杀死细菌。
• PHTHALANILATE COMPOUNDS AND METHODS OF USE
  申请人：Mobashery Shahriar

  公开号：US20120232150A1

  公开（公告）日：2012-09-13

  The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo.
• LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM
  申请人：American University of Cairo

  公开号：US20150328329A1

  公开（公告）日：2015-11-19

  Ligands that target the HCV-E2 binding site and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of E2 binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds. Identification and design of groups of compounds that bind to CD81 for use as therapeutics for treating patients infected by Hepatitis C virus and other viruses that interact with CD81. By binding to CD81, these molecules can block 1) HCV and other viral entry into cells (infection), 2) inflammatory responses caused by HCV and other viral infections, and 3) the induction of HCV associated cancers.
• US8859620B2
  申请人：——

  公开号：US8859620B2

  公开（公告）日：2014-10-14
• [EN] LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM<br/>[FR] LIGANDS QUI CIBLENT DES SITES DE LIAISON DE E2 DE VHC SUR CD81 ET PROCÉDÉS THÉRAPEUTIQUES LES EMPLOYANT
  申请人：AZZAZY HASSAN

  公开号：WO2014081856A2

  公开（公告）日：2014-05-30

  Ligands that target the HCV-E2 binding site and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of E2 binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds. Identification and design of groups of compounds that bind to CD81 for use as therapeutics for treating patients infected by Hepatitis C virus and other viruses that interact with CD81. By binding to CD81, these molecules can block 1) HCV and other viral entry into cells (infection), 2) inflammatory responses caused by HCV and other viral infections, and 3) the induction of HCV associated cancers.